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Background: Non-malignant chronic pain (NMCP) is one of the most common reasons for primary care visits. Pain
management health care disparities have been documented in relation to patient gender, race, and socioeconomic
status. Although not studied in relation to chronic pain management, studies have found that living in a rural
community in the US is associated with health care disparities. Rurality as a social determinant of health may
influence opioid prescribing. We examined rural and non-rural differences in opioid prescribing patterns for NMCP
management, hypothesizing that distinct from education, income, racial or gender differences, rural residency is a
significant and independent factor in opioid prescribing patterns.
Methods: 2010 National Ambulatory Medical Care Survey (NAMCS) data were examined using bivariate and
multivariate techniques. NAMCS data were collected using a multi-stage sampling strategy. For the multivariate
analysis performed the SPSS complex samples algorithm for logistic regression was used.
Results: In 2010 an estimated 9,325,603 US adults (weighted from a sample of 2745) seen in primary care clinics
had a diagnosis of NMCP; 36.4% were prescribed an opioid. For US adults with a NMCP diagnosis bivariate
analysis revealed rural residents had higher odds of having an opioid prescription than similar non-rural adults
(OR = 1.515, 95% CI 1.513-1.518). Complex samples logistic regression analysis confirmed the importance of rurality
and yielded that US adults with NMCP who were prescribed an opioid had higher odds of: being non-Caucasian
(AOR =2.459, 95% CI 1.194-5.066), and living in a rural area (AOR =2.935, 95% CI 1.416-6.083).
Conclusions: Our results clearly indicated that rurality is an important factor in opioid prescribing patterns that cannot
be ignored and bears further investigation. Further research on the growing concern about the over-prescribing of
opioids in the US should now include rurality as a variable in data generation and analysis. Future research
should also attempt to document the ecological, sociological and political factors impacting opioid prescribing
and care in rural communities. Prescribers and health care policy makers need to critically evaluate the implications
of our findings and their relationship to patient needs, best practices in a rural setting, and the overall consequences of
increased opioid prescribing on rural communities.
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Chronic pain, commonly defined as the experience of epi-
sodic or continuous debilitating pain over time (weeks to
months or longer), is a significant problem in the United
States [1-4]. It is a phenomenon with a complex etiology
manifest with both physical and psychological compo-
nents [4-6]. At present nearly 1 in 3 or 100 million adults
in the US suffer from chronic pain [4,6]. Chronic pain in
the US is estimated to cost approximately $560-$635 bil-
lion annually, an amount equal to about $2,000 per capita
[6]. This cost estimate includes both direct and indirect
costs that are approximately equal to one another.
Chronic pain adversely impacts communities, families,
and individuals by significantly contributing to poor
mental and physical health resulting in lost work prod-
uctivity and disability [4-7]. In the US, non-malignant
chronic pain (NMCP) is one of the most common rea-
sons for primary care visits [1,3,8,9]. At times when pa-
tients visit a healthcare professional for NMCP, inadequate
training and resources may prevent proper assessment
and management [7,10,11]. Pain management health-
care disparities have been documented in relation to
patient gender [12,13], race [3,11,14-16], and socioeco-
nomic status [12,17]. Although not studied in relation
to chronic pain management, studies have found that
living in a rural community in the US is associated
with healthcare disparities [18].
Opioids are commonly used in chronic pain manage-
ment. Opioids are being overprescribed with possible
negative consequences for individuals, families and com-
munities. These consequences include: unintended death
[7], overdose [7], diversion [7], and crime [7]. There is
an upward trend for overprescribing opioids. Rurality as
a social determinant of health may influence opioid pre-
scribing [18]. Some research has been conducted on dif-
ferent types of chronic pain and opioid prescribing
patterns including a geographic variable in the analysis.
However, none of these studies undertook the task of an-
swering a question about opioid prescribing and NMCP
in rural versus non-rural adults using patient level health
records [19-22]. This has created an epidemiological gap
in our knowledge regarding opioid prescribing patterns
for rural adults with NMCP.
Rasu, et al. [4] studied chronic pain management
(medication and non-medication) in US ambulatory
care settings. While they described the characteristics
of their patient population, they did not examine the
associations between patient characteristics and variations
in prescribing patterns. They concluded that additional re-
search should investigate patterns of NMCP management
in various populations. Others [23,24] have done this, but
with older data. One study included geographic location of
physician practice site in their analyses using rural locale as
the reference category in multivariate analyses and foundno significant relationship to opioid prescribing [25]. In
this paper we hypothesize that distinct from patient race,
education, income or gender, rural residency is a significant
and an independent risk factor for the greater probability
of receiving an opioid prescription for NMCP.
Methods
To answer the research question, 2010 National Ambulatory
Medical Care Survey (NAMCS) data were examined using
bivariate and multivariate techniques. NAMCS is designed
to collect data on the utilization and provision of ambulatory
care services nationwide. Data are collected from a national
sample of ambulatory care visits. The survey employs a
complex four-stage probability sampling design. A descrip-
tion of the sampling strategy is discussed elsewhere [25].
The 2010 NAMCS data were used for this study because
they were the most recently available data. These data are
weighted to be nationally representative of patient health
records.
All analyses were performed on weighted data as is
recommended by the Center for Disease Control and
Prevention’s (CDC) National Center for Health Statistics
(NCHS). The weighting, as calculated, uses the most re-
cently available census data to provide a stratified rep-
resentation of the nation’s patient population. Results
report weighted data.
The survey uses a Patient Record Form as the survey in-
strument. The NAMCS patient record form is completed
by ambulatory care staff for a systematic random sample of
patient visits during a randomly assigned 1-week reporting
period. Data are obtained on demographic characteristics
of patients, expected source(s) of payment, patients’
complaints, diagnoses, diagnostic/screening services, pro-
cedures, medication therapy, disposition, types of pro-
viders seen, causes of injury, and certain characteristics of
the facility, such as geographic region and metropolitan
status.
Rurality, one of the key independent variables in this
analysis, was derived using Metropolitan and Micropoli-
tan Statistical Area (MSA) methodology. This is a defin-
ition used by federal level agencies for research purposes.
MSA was recoded into the dichotomous categories of
rural or non-rural. Rural residents were defined as people
living either within an MSA that had no center city or out-
side an MSA. Non-rural residents included all respon-
dents living in a center city of an MSA, outside the center
city of an MSA but inside the county containing the cen-
ter city, or inside a suburban county of an MSA.
The study population for this research was US adults
with NMCP. NMCP is defined as pain lasting 3 months
or more or as pain persisting beyond the time of ex-
pected healing. The three-digit ICD-9 code for NMCP
is 338.2. The covariates or independent variables for
this research were: geographic locale (rural/non-rural),
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Non-Caucasian), age ranges (18-39/40-64/65 years and
older), education attainment in a patient’s zip code
(≤20% of adults with a university degree/> 20% of
adults with a university degree), poverty level in pa-
tient’s zip code (<10%/≥ 10%) health insurance status
(insured/noninsured), primary health care provider (HCP)
seen (yes/no), depression diagnosis (yes/no), arthritis diag-
nosis (yes/no). Depression and arthritis diagnoses were in-
cluded as variables because these may influence opioid
prescribing [26,27]. All of the study covariates were
recoded from their original configuration for analyses.
Re-coding entailed either collapsing categories and/or
removing unknown responses. Opioid prescription was
the dependent variable for this study.
The study variable that entailed complicated re-coding
was the dependent variable—opioid prescription. Using
the CDC’s New Ambulatory Care Drug Database System
for NAMCS Data, prescribed drugs were classified as
opioid or other. Table 1 displays the opioid drug codes
by generic drug name.
Statistical Package for Social Scientists (SPSS, IBM,
Chicago, IL, version 21.0) was used to complete all stat-
istical analyses and alpha was set at p < 0.05. Bivariate
contingency table analysis was conducted to establish
the relationships between each of the covariates and the
dependent variable. Bivariate analysis tests for a statisti-
cally significant relationship between an outcome or
dependent variable and a predictor or independent vari-
able. Bivariate analysis is not a stratified analysis. SPSS
allows an unadjusted odds ratio to be computed from
the contingency table analysis as long as the contingency
table is a 2 × 2 table. If not, then a chi square may be
computed as the test statistic for differences between
percentages (e.g., 3-group age ranges and opioid pre-
scription). Logistic regression analysis, to produce ad-
justed measures, was performed using SPSS (version
21.0) complex samples. The complex samples algorithm
was used to account for the stratified, clustered, and
weighted variables in the 2010 NAMCS survey data.
This was essential since NAMCS data are collected
using a survey design where a nationally representative
sample of physicians and practice sites are examined and
sample weights applied to obtain national population-
based statistics. Detailed documentation of the NAMCS
instrument, methodology, and data files that served as
the basis for this study is available elsewhere [25]. The
multivariate logistic regression model was performed
using opioid prescription as the dependent variable, and
adjusted odds ratios were produced to test significance
and establish effects sizes. US adults with a diagnosis of
NMCP was the population examined. For analysis the
sample of 2,745 was weighted to represent 9,325,603 US
adults with a diagnosis of NMCP.The Institutional Review Boards (IRBs) at all of the re-
searchers’ institutions recognize that the analysis of de-
identified, publicly available data does not constitute hu-
man subjects research as defined in federal regulations
and as such does not require IRB review. Hence, human
subjects’ approval was not necessary since this was a de-
identified data only study.
Results
An estimated 9,325,603 US adults with a diagnosis of
NMCP were seen in primary care clinics in 2010 in the US.
Table 2 displays data describing the study population –- US
adults with NMCP. The data are displayed by the inde-
pendent covariates and the dependent variable (opioid pre-
scription) and are those used to perform the complex
samples logistic regression analysis. Missing data were re-
moved from the analysis as displayed in Table 2.
The majority of the population 94.4% had health insur-
ance and 66.4% were reported as having seen their pri-
mary HCP. Over seventy percent (73.7%) of the study
population were women and 79.4% were Caucasian. In
terms of the dependent variable 36.4% of the adult popu-
lation with NMCP had an opioid prescription.
Bivariate analysis performed indicated that all of the
study’s independent variables or covariates were signifi-
cantly associated with the dependent variable (Table 3).
Most importantly this bivariate analysis revealed that
rural adults with NMCP had higher odds (OR =1.515,
95% CI =1.513 – 1.518) than similar non-rural adults of
having a prescription for opioids.
Complex samples logistic regression was performed
and the results are displayed in Table 4. Based on the bi-
variate analysis all of the study covariates were entered
into the complex samples logistic regression model.
Analysis yielded that two covariates were significantly
associated with the dependent variable–-rural residency
(AOR =2.935, 95% CI 1.416-6.083) and non-Caucasian
race/ethnicity (AOR =2.459, 95% CI 1.194-5.066).
Discussion
Recently there has been much concern expressed about
the over-prescribing of opioids [7,28-30]. This concern
arises from the fact that opioids are potentially addictive
which can lead to misuse. Opioids have been cited as
contributing to unnecessary morbidity and mortality,
and in the long-run contribute to potentially unneces-
sary medical costs [4,28]. We were interested in examin-
ing differences in rural and non-rural opioid prescribing
patterns for NMCP management, hypothesizing that dis-
parities exist in opioid prescribing patterns for rural
populations in the US. Our analyses supported our hy-
pothesis that rural residency is an independent risk fac-
tor for a greater probability of patients with NMCP
being prescribed an opioid.
Table 1 Opioid drug codes by generic drug name
Opioid drug codes from NAMCS drug database Generic drug name




2333, 5081, 5091, 8246, 9582, 22303, 91047, 96109, 97181 Oxycodone
7117, 7223, 21575 Oxymorphone
23285, 30535, 30540 Pentazocine
8338 Phenerol
7420, 8475, 8490, 10115 Propoxyphene
91046, 92044, 92070, 98144, 99123 Morphine
21550, 60990 Nalbuphine
8606, 98067 Narcotic Analgesics





200, 8785, 18760, 96045 Meperidine
10130, 18985 Methadone
85, 2852, 3228, 8079, 10743, 19650, 19699, 26763, 41420, 60940, 70214 Morphine
91071 Dezocine
9574 Dihydrocodeine
2067, 3307, 7197, 9508, 29645, 60565, 92024, 94188 Fentanyl
14770, 92041, 92042 Homatropine Methyl Bromide-Hydrocodone
7582, 9435, 14955, 94184 Hydrocodone
9600, 9641, 15005 Hydromorphone
11225, 22415, 27315 Aspirin; Caffeine; Codeine; Phenacetin
11090, 18425, 24770, 25525 Aspirin; Caffeine; Phenacetin; Propoxyphene
8910 Atropine; Opium; Phenacetin; Salicylamide
5054, 60265, 95036 Buprenorphine
5103 Butalbital-Codeine
1021, 29285 Butorphanol
1028, 7180, 7185 7190 Codeine
25690 Codeine; Sanguinaria; Terpin Hydrate; White Pine
Syrup; Wild Cherry Syrup
91012 Dezocine
10715 Acetaminophen; Aspirin; Caffeine;
Dihydrocodeine
42245 Acetaminophen; Aspirin; Caffeine; Hydrocodone
40765 Acetaminophen; Butabarbital; Codeine
13152, 24143 Acetaminophen; Butalbital; Codeine
866, 96145 Alfentanil
21095 Alphaprodine
2730, 2735 Aluminum Hydroxide; Aspirin; Codeine;
Magnesium Antacids
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Table 1 Opioid drug codes by generic drug name (Continued)
2740 Aluminum Hydroxide; Aspirin; Codeine;
Magnesium Hydroxide
12560 Aspirin; Butalbital; Caffeine; Codeine; Phenacetin
45, 50, 55, 65, 1990, 2815, 2825, 11220 Aspirin; Caffeine; Codeine; Phenacetin
3520 Acetaminophen; Codeine; Salicylamide
6284 Acetaminophen; Ethanol; Glycerin; Hydrocodone;
Parabens
250, 265, 270, 275, 280, 1758, 2340, 2345, 5151, 5640, 7080, 7165, 7618, 9538, 11265, 11268, 23665,




251, 1268, 1995, 2045, 2082, 2132, 2314, 3518, 6059, 7064, 8354, 10105, 14917, 34110, 40860, 60340,
61610, 89038, 89039, 92180, 93077, 93089, 96028, 96047, 98036, 98168
Acetaminophen-Hydrocodone
8790 Acetaminophen-Meperidine
283, 2348, 3394, 7251, 7252, 7632, 8248, 22305, 22306, 23385, 26958, 28272, 32945, 91048, 99114 Acetaminophen-Oxycodone
7701, 30513 Acetaminophen-Pentazocine
156, 6232, 8470, 25530, 25545, 28340, 34985, 61240, 89071, 89072, 93053, 93411 Acetaminophen-Propoxyphene
11689, 95178 Apap; Butalbital; Caffeine; Codeine
44, 3078, 7467, 93351 Apap; Caffeine; Dihydrocodeine
12555, 12565, 12570, 15983, 40020 Asa; Butalbital; Caffeine; Codeine
30340 Asa; Caffeine; Dihydrocodeine
4215, 8480, 10120, 25505, 25515, 25520, 28345, 41375 Asa; Caffeine; Propoxyphene
5018 Aspirin; Buffers; Codeine
10285 Aspirin; Caffeine; Dover’s Powder
105, 2803, 2820, 11230, 11235, 11240, 11245, 11250, 11255, 11260 Aspirin-Codeine
8397, 92181, 93027 Aspirin-Hydrocodone









9737, 9751, 98043 Hydrocodone-Ibuprofen
5040 Ibuprofen-Oxycodone
1098, 4534, 8093, 18755, 96012 Meperidine-Promethazine
4538 Naloxone-Pentazocine
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idents had higher odds of having an opioid prescription
than similar non-rural adults. Rural residency was the
strongest predictor for having an opioid prescription and
a diagnosis for NMCP. Second, being non-Caucasian was
a strong predictor of having an opioid prescription and a
diagnosis for NMCP.Our results clearly indicate that rurality is an import-
ant factor in opioid prescribing patterns that cannot be
ignored and bears further investigation. This is in stark
difference to the finding of an earlier paper [24] that
found no relationship between opioid prescription and
geographic locale. At first glance one might conclude
that this finding indicates an opioid prescribing disparity,
Table 2 Description of the study population (adults with
NMCP) for SPSS complex samples logistic regression
analysis
Variables and Factors Weighted N* Weighted %
Patient sex Female 6868340 73.7
Male 2457263 26.3
Patient age 18-39 565172 6.1
40-64 4070522 43.6
> = 65 4689909 50.3




in patient zip code
<20% 5001646 53.6




> = 10% 4337368 46.5
Health Insurance
status


















Opioid prescription** Other Medications 5928705 63.6
Opioids 3396898 36.4
*This weighted n is derived from a sample size of 2745, of which 2272 (82.8%) were
non-rural residents and 473 (17.2%) rural residents.
**Study Dependent Variable.
NAMCS 2010 Data (weighted n =9,325,603).
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are not disparities. Disparities arise when the differences
are avoidable as well as unjust [3,18]. We cannot say with
any certainty that these are the characteristics of the dif-
ferences revealed in prescribing patterns from our ana-
lyses. It may be that there are treatment option limitations
in rural areas of the US [31]. Ultimately, NMCP is com-
plex and often requires a multifactorial approach for opti-
mal management [32]. For instance, physical therapy,
occupational therapy, massage therapy, acupuncture, inte-
grated specialty pain management services, or behavioral
modification may be useful approaches for the manage-
ment of patients with NMCP [33]. These modalities as
treatment options may be less available to patients in the
rural US [31].
Our findings also identified that non-Caucasian race/
ethnicity (African American, Hispanic, Asian, Native
American, and multiracial) was an independent riskfactor for having NMCP and being prescribed an opi-
oid. Opioid prescribing patterns for non-Caucasian
adults is complicated and the differences between our
findings and those from a number of other studies are
hard to reconcile or explain. Findings from multiple
studies have yielded that African American or Black
patients were less likely than Caucasian ones to be pre-
scribed opioids for pain [12,15,16,19,34-37]. Other re-
search has revealed that in the US there is little difference
in the estimated prevalence of pain across population
groups [38]. However, racial/ethnic minorities have often
had inadequate pain management despite being more
likely to report experiencing severe pain and/or pain that
interfered with daily activities [3,38]. One explanation for
the variance of our findings from other studies might be
the examination of data from a different source. The
NAMCS data analyzed in this study is derived from pa-
tient health records rather than patient self-report surveys.
Patient health record data are based on documented visits
to health care providers, while patient self-report data are
not. We do not want to make a claim of the veracity of
one source of data over the other, only that the analysis of
each may yield different findings.
Study limitations and strengths
This study does have some limitations, most of which
are attributable to how the survey data were collected.
First, ICD-9 codes were used to identify patients with
NMCP and to limit the population included in the study.
Second, opioid prescriptions were then assumed to be
linked to the NMCP patient population. Since there is
no link in the questionnaire form between prescribed
medications (in our case opioids) and diagnosis (ICD-9
codes), we were unable to determine with surety for what
diagnosis opioids were being prescribed for. However, this
limitation is also present in a previously published study
[4], setting precedence for using this methodology. Studies
that can determine causality amongst these variables are
warranted. Third, the variables of race/ethnicity, educa-
tion, and household income were derived variables.
Nevertheless, this study has a number of strengths.
Since we used national patient record population-level
survey data, we had a large data set that was weighted to
ensure that our findings could be more easily and accur-
ately generalized to the US population. Another strength
is the magnitude of the effect sizes for rural and non-
rural opioid prescribing patterns as well as those de-
tected for race/ethnicity. The effect sizes, derived from
the logistic regression odds ratios, ranged from nearly
two to three times greater than the reference categories.
Much has been studied in reference to age and race/eth-
nicity, but these findings lend vigorous support to the
conceptualization of rurality as a social determinant of
health.
Table 4 SPSS complex samples logistic regression
analysis of US adults with NMCP (study dependent
variable = opioid prescription)
Variables Factors Adjusted odds
ratio (95% CI)
Patient sex Female 1.310 (.631, 2.720)
Male --*
Patient age 18-39 1.094 (.297, 4.027)
40-64 1.949 (.977, 3.887)
> = 65 --*
Race/Ethnicity Caucasian --*
Non-Caucasian 2.459 (1.194, 5.066)
Education percent of
university graduates
in patient zip code
<20% --*
> = 20% 1.031 (.489, 2.175)
Poverty percent in
patient zip code
<10% 1.713 (.876, 3.351)
> = 10% --*
Primary HCP visit Yes 1.162 (.515, 2.621)
No --*










Yes .518 (.246, 1.089)
No --*
Geographic locale Rural 2.935 (1.416, 6.083)
Non-Rural --*
*Reference category.
NAMCS 2010 data (weighted n =9,325,603).
Table 3 Bivariate analysis of US adults with a diagnosis of chronic pain and an opioid prescription as dependent
variable by covariates
Variable Factor Unadjusted odds ratio (95% CI)
Patient sex (vs. Male) Female 1.107 (1.104, 1.109)
Patient Race/Ethnicity (vs. Non-Caucasian) Caucasian .643 (.642, .644)
Education percent university graduate in patient zip code (vs. > = 20% ) <20% 1.010 (1.008, 1.012)
Poverty percent in patient zip code (vs. > = 10%) <10% 1.036 (1.034, 1.037)
Health Insurance status (vs. Do Not Have Health Insurance) Have Health Insurance 1.010 (1.006, 1.014)
Primary HCP visit (vs. No) Yes 1.192 (1.190, 1.194)
Patient now has arthritis (vs. Yes) No .885 (.883, .886)
Patient now has depression (vs. Yes) No 1.299 (1.295, 1.302)
Geographic local (vs. Non-Rural) Rural 1.515 (1.513, 1.518)
Variable Factors % Significance
Patient age range 18-39 6.1 < .001
40-64 43.6
> = 65 50.3
2010 NAMCS (weighted n =9,325,603).
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This study fills an important epidemiological knowledge
gap regarding opioid prescribing patterns for rural adults
with NMCP. Further research on the growing concern
about the over-prescribing of opioids in the US should
now include rurality as a variable in data generation and
analysis in addition to the variable of race/ethnicity that
are commonly included. In order to provide the best
level of care to all patients regardless of geographic loca-
tion or race/ethnicity, another level of analysis should
capture data on opioid dosing and health care provider
perceptions of patients. Future research should also at-
tempt to document the ecological, sociological and polit-
ical factors impacting opioid prescribing and care in
rural communities. Prescribers and health care policy
makers need to critically evaluate the implications of our
findings and their relationship to patient needs, best
practices in a rural setting, and the overall consequences
of increased opioid prescribing on rural communities.
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